Janssen Pharmaceuticals (Janssen) has announced that it has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase 1 and expected to enter phase 2 studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
GlaxoSmithKline (GSK) has received approval from the US Food and Drug Administration (US FDA) for its Biologics License Application (BLA) for Nucala (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Nucala is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778. Financial terms of the transaction have not been disclosed.
Bloomage BioTechnology Corporation ("Bloomage BioTech" or "the Company"; together with its subsidiaries, collectively referred to as "the Group") and GIC, Singapore's sovereign fund, jointly announced an investment agreement, pursuant to which GIC will become a key shareholder of the Company by subscribing for its shares to support the Company in building up the aesthetic medical ecosystem in China through organic growth and acquisitions.
ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, and Hyundai Pharm Co. Ltd. (Hyundai), a leading Korean pharmaceutical company, have entered a collaboration and licence agreement to develop and commercialise ASLAN001 (varlitinib) for the treatment of cholangiocarcinoma (CCA)in South Korea.
ASLAN001 is a potentially best-in-class small molecule pan-HER inhibitor targeted for cholangiocarcinoma, an aggressive form of bile duct cancer with no approved therapy and a very poor prognosis, and is also being studied in gastric and breast cancer. Worldwide, South Korea has one of the highest prevalence rates of cholangiocarcinoma and gastric cancer, with 4,000 and 30,000 new patients diagnosed annually respectively
Carl Firth, Chief Executive Officer and Founder, ASLAN Pharmaceuticals
North Asia has been leading Asia and even in some aspects, the world in producing novel therapies and drugs to combat everything from Alzheimer’s and dementia to rare diseases. But Southeast Asia, in particular, Singapore, Thailand, Malaysia and Indonesia have been souring under the radar, going through key clinical trials to one day commercialize key treatments for the world. Can Southeast Asia one day lead the world in producing novel therapies?
Dr. Chet Yong,Healthcare Sector Leader, Deloitte Southeast Asia
In the light of stimulating and encouraging innovation in its pharmaceutical industry, China has established a three-year pilot scheme to ease approvals for new drugs, said China's drug and food regulator.
According to the China Food and Drug Administration, the trial will be launched in 10 different regions across China, and it will allow R&D organizations to quickly seek drug approvals, which are currently restricted only to drug manufacturers.
MabSpace Biosciences, a Suzhou antibody company, raised $15 million in a Series A funding, all of which came from Lilly Asia Ventures. MabSpace's proprietary technology breaks the tolerance of the immune system for human/mouse antigens that are not recognized as foreign. MabSpace has formed several partnerships with other pharmas, and it is also developing its own portfolio of drug candidates.
In a release, the company said the cash will "be used to advance MabSpace's pipeline of therapeutic antibody programs into clinical studies, and enable expanded discovery of novel antibodies aimed at various components of tumor microenvironment to enhance responses of tumors that may be less likely to respond to T cell checkpoint monotherapy."
During an interview Xueming Qian, Ph.D., Chairman and CEO, Mabspace Biosciences, tells The Biotechnician about his latest funding from Lilly and the future of his company in producing antibody therapeutics for cancer treatment.
The Biotechnician-How is your team planning on investing the new $15m investment from Lilly?
In late October 2015, Anteo Diagnostics announced that it had entered into a non-exclusive distribution agreement with KomaBiotech (Koma), who will market, distribute and support Anteo Mix&Go (AMG) products across South Korea. The agreement with Koma is seen as a major step into developing a strong sales channel into South Korea, and continuing to implement its multifaceted revenue model across the globe.
Anteo’s CEO, Dr. Geoff Cumming believes that the agreement with Koma will give them the support on the ground that they need to sell their Anteo Mix&Go (AMG™) products. Anteo’s CEO, Dr. Geoff Cumming, commented, “We are pleased to be able to work with Koma, an established market leader in South Korea, which has a long and respected history of servicing this region. Having a partner like Koma, which is expert in sales, marketing and the provision of quality customer support in the South Korean market, is important for Anteo."
The Biotechnician produces daily news and intelligence on the most creative biotechnology and drug developments across the Asia Pacific. With experts and editors across Asia, The Biotechnician comments on breaking news while it occurs, and provides an insightful perspective to Asian based biotechnology firms, the development of medicines in the region, transactions that are occurring in the market, and regulatory issues that are preventing the development of the industry across the region.